Något negativ organisk tillväxt… Den organiska tillväxten var svagt negativ i Q2, vilket vi bedömer ...
Redeye provides a research update on Lipum following the Q3 report published by the company earlier ...
Redeye’s first comments follow this morning’s Q3 report from Tagmaster.
Solid Q3 and limited estimate revisions Divestments and long-term swaps to protect the ICR.
Consti’s steady development continued with slightly higher than expected growth during the Q3.
Vaisala delivered strong profitability amid a difficult market for Q3.
DT’s cost measures were visible in Q3 figures, and SBU-driven growth is to show more earnings gains ...
Suominen’s earnings still missed estimates as top line remained very soft.
Minor estimate changes ahead of Q3 Opportunistic entry into Venezuela P/NAV of 0.
Ahead of Cibus' Q3 2023 report, we trim our estimates to reflect changes in interest rates.
Redeye retains its positive view of Proact following a solid Q3 report, with the positive highlights...
Q3'23 report due on Tuesday 7 November First revenue contribution from Al Jumd in Q3e P/NAV of 0.
Redeye takes you inside Gapwaves' headquarters to delve deeper into its recent quarter's performance...
10% org. growth, 3% EBIT miss, good Q4 guidance 28% adj.
Ahead of Boreo’s Q3 report, due on 2 November, we maintain our estimates intact.
Aptahem har publicerat bolagets rapport för tredje kvartalet 2023 där följande är vår uppföljande ko...
Addvise, som förvärvar bolag inom hälso- och sjukvård, bjöd på ett starkt tredje kvartal.
- Sales-1% and adj. EBITA +9% vs. ABGSCe - Leverage down to 2.
Redeye provides a more indepth take on Episurf Medical’s Q3 report.
Serieproduktion av NLAW-IMUer startade i slutet av tredje kvartalet Nettoomsättningen ökade med 29% ...
